The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | SF3B1 as therapeutic target in FLT3/ITD positive AML
Jacqueline Cloos, PhD, of Amsterdam UMC, Amsterdam, The Netherlands, outlines the findings of a study investigating splicing factor 3B subunit 1 (SF3B1) as a therapeutic target in patients with acute myeloid leukemia (AML) and an internal tandem duplication (ITD) in the FMS-like tyrosine kinase 3 (FLT3) gene. Dr Cloos describes how AML cells carrying spliceosome mutations are susceptible to SF3B1 modulation, meaning the development of a therapeutic modulator could be a viable treatment method. It was found that ITD/FLT3 AML cells treated with the SF3B1 modulator, E7107, were particularly susceptible to inhibition due to disruption of the cell cycle; however, overall survival was not seen to improve significantly. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Jacqueline Cloos, PhD, has received institutional research funding from Genentech, BD Biosciences, Novartis, Takeda Pharmaceuticals and Merus; royalties from BD Biosciences and Navigate; and MRD assessments from DC Prime, Helsinn, Janssen, Merus and Novartis.
